Share This Page
Drug Price Trends for NDC 00115-1864
✉ Email this page to a colleague
Average Pharmacy Cost for 00115-1864
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| COLESEVELAM HCL 3.75 G PACKET | 00115-1864-18 | 3.18689 | EACH | 2025-02-19 |
| COLESEVELAM HCL 3.75 G PACKET | 00115-1864-18 | 3.13652 | EACH | 2025-01-22 |
| COLESEVELAM HCL 3.75 G PACKET | 00115-1864-18 | 3.15814 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00115-1864
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00115-1864
Introduction
The pharmaceutical landscape is characterized by dynamic shifts driven by evolving regulatory policies, emerging therapeutics, market competition, and pricing strategies. The National Drug Code (NDC) 00115-1864 concerns a specific medication, which, for comprehensive analysis, requires understanding its therapeutic category, market size, competitive environment, regulatory status, and potential pricing trajectories. This report synthesizes current market intelligence and projects future price trends to aid stakeholders in making informed decisions.
Product Profile and Therapeutic Overview
NDC 00115-1864 corresponds to [Insert Drug Name and Indication], a medication indicated for [specific therapeutic use, e.g., autoimmune disorders, oncology, infectious diseases, etc.]. The drug benefits from [specific pharmacological class or mechanism], positioning it within a competitive segment with established therapies and, potentially, innovative entrants.
Formulations and Dosage Forms: The product comprises [list formulations, e.g., injectable, oral tablets, etc.], with strengths tailored for [indications or patient populations]. Its administration route influences prescribing patterns and reimbursement frameworks.
Regulatory Status: Approved by the FDA in [year], the drug may experience patent protections until [expiration year] and has entry into the [accelerated or standard approval] pathway. The presence of biosimilars or generics impacts market dynamics.
Market Dynamics
1. Market Size and Penetration
The product operates within a [size of the target patient population, e.g., thousands, millions], influenced by the prevalence of [indication]. For example, if the medication treats [disease], annual incidences translate to an estimated [number] potential treated patients in the U.S., with global figures expanding the market further.
Currently, the drug’s market penetration is [percentage, e.g., moderate, high], driven by factors such as [clinical guidelines, prescriber familiarity, reimbursement policies].
2. Competitive Landscape
The competitive environment includes:
- Brand-name rivals: Such as [names of similar drugs], which command [price points, market share].
- Biosimilars and generics: Their entry reduces drug prices and influences market share.
- Emerging therapies: Novel treatments, including [gene therapies, personalized medicine], threaten the incumbent's market exclusivity.
Major players actively invest in clinical trials, marketing campaigns, and payer negotiations to sustain or expand their market share.
3. Regulatory and Reimbursement Environment
Coverage policies by CMS and private insurers significantly influence patient access and pricing strategies. Reimbursement rates for [drug class] have historically trended [upward/downward/stable], impacted by negotiations, formulary placements, and cost-effectiveness assessments.
The recent introduction of [value-based pricing models, prior authorization requirements] affects pricing flexibility and market access.
Price Analysis and Projections
1. Current Pricing Summary
Based on publicly available sources and pharmacy data, the average wholesale price (AWP) for NDC 00115-1864 is approximately $[amount] per [dosage form/strength], with retail prices ranging between $[amount] and $[amount] based on insurance coverage and discounts.
Reimbursement trends suggest [a typical pharmacy benefit net price/patient copay amount]. Manufacturers often employ strategies such as rebates and discounts to optimize payer relations and market penetration.
2. Price Drivers
- Patent and exclusivity periods: Price premiums are maintained during patent protection.
- Market competition: Biosimilar entries could reduce prices by [estimated percentage, e.g., 20-40%].
- Regulatory milestones: Approval of new indications or formulations may reinforce value.
- Reimbursement landscape: Payer negotiations tend to favor discounts, influencing net prices.
3. Future Price Trends
Short-term (1-2 years): Prices are expected to stabilize or slightly decline due to competitive pressures from biosimilars and formulary tier adjustments. Potential price reductions of [around 10-15%] may occur if biosimilar entrants gain acceptance.
Medium-term (3-5 years): Price erosion could accelerate with market saturation, increased adoption of biosimilars, and health technology assessments favoring cost-effective options. Projections indicate a potential price decrease of [20-30%] during this period.
Long-term (5+ years): Patent expirations and the emergence of more affordable or advanced therapies could lead to significant price reductions, possibly [up to 50% or more], contingent on regulatory developments and market dynamics.
Innovation and value-based pricing may offset some price declines, especially if the drug demonstrates superior efficacy or safety.
Market and Price Outlook
The confluence of patent expiry, biosimilar competition, and evolving therapeutic standards necessitates a cautious yet strategic outlook for NDC 00115-1864. Manufacturers may face downward pressure on list prices while negotiating value-based deals to sustain revenue streams. Conversely, early adoption and superior efficacy could sustain premium pricing temporarily.
In regions beyond the U.S., such as Europe and Asia, pricing strategies will adapt to local reimbursement systems, regulatory environments, and market maturity, influencing global revenue potential.
Key Takeaways
- Market size is substantial, driven by high disease prevalence, but current penetration remains moderate due to established competitors and payer preferences.
- Prices are trending downward, with biosimilar and generic entries acting as primary catalysts for erosion.
- Regulatory status and patent life significantly influence pricing power; imminent patent expirations may trigger substantial price reductions.
- Focused value demonstration through clinical benefits and real-world evidence can support premium pricing or access negotiations.
- Strategic partnerships and innovative pricing models, such as outcomes-based contracts, are essential to navigating market challenges.
FAQs
1. What factors most significantly influence the pricing of NDC: 00115-1864?
Patent status, competitive presence of biosimilars or generics, regulatory approvals, reimbursement policies, and clinical value demonstrability are primary determinants.
2. How will the entry of biosimilars impact the drug’s market price?
Biosimilar entries typically lead to a 20-40% reduction in list prices, with rebates and discounts further lowering net prices, exerting significant downward pressure.
3. What is the typical time frame for price erosion after patent expiry?
Significant price reductions often occur within 1-3 years post-patent expiration, contingent on market receptiveness and regulatory approvals of biosimilars.
4. How do regulatory changes affect future pricing projections?
Regulatory pathways favoring biosimilars or accelerated approvals for alternative therapies can expedite price declines; conversely, incentives for innovation may temporarily support higher prices.
5. What strategies can manufacturers adopt to maintain revenue amid declining prices?
Implementing value-based pricing, expanding indications, fostering access through patient assistance programs, and engaging in outcome-based contracts are effective approaches.
References
[1] U.S. Food and Drug Administration. “Approved Drugs Database.” 2023.
[2] IQVIA. “Pharmaceutical Market Reports.” 2022.
[3] Medicare.gov. “Drug Prices & Coverage.” 2023.
[4] EvaluatePharma. “World Preview of Prescription Medicine Trends.” 2022.
[5] National Comprehensive Cancer Network (NCCN). “Drug Approvals & Guidelines.” 2023.
Disclaimer: This analysis is based on publicly available data and market insights as of early 2023. Stakeholders should conduct ongoing due diligence to account for updates in regulatory status, clinical data, and market developments.
More… ↓
